Daniel Abdun-Nabi - 01 Jun 2023 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
Director
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Issuer symbol
APVO
Transactions as of
01 Jun 2023
Net transactions value
$0
Form type
4
Filing time
02 Jun 2023, 16:43:05 UTC
Previous filing
10 Aug 2022
Next filing
10 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +297 +6.6% 4,768 01 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -297 -50% $0.000000 298 01 Jun 2023 Common Stock 297 Direct F1, F2
transaction APVO Restricted Stock Unit Award $0 +3,571 $0.000000 3,571 02 Jun 2023 Common Stock 3,571 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.
F3 The RSUs vest in full on the first anniversary of the date of grant.